Baird analyst Ghansham Panjabi said weak volumes and an unfavorable cost/spread continue to weigh on Berry Global shares, but at this point the shares appear oversold. The analyst believes its free cash flow and volume outlook are move favorable and he sees pricing pressures easing over the next 2-3 quarters. Panjabi reiterated his Outperform rating and lowered his price target to $65 from $70 on Berry Global shares.

Berry Global (BERY) and Glatfelter (GLT) announced the achievement of a regulatory milestone in the proposed transaction involving the combination of a majority of Berry's Health, Hygiene and Specialties segment to include its Global Nonwovens and Films business, or HHNF, with Glatfelter, with the expiration of the required waiting period under the Hart-Scott-Rodino, or HSR, Antitrust Improvements Act. As previously announced on February 7, Berry and Glatfelter entered into a definitive agreement under which Berry will spin-off and merge its HHNF business with Glatfelter in a Reverse Morris Trust transaction. The transaction will create a leading, publicly-traded company in the specialty materials industry. The transaction is expected to close in the second half of calendar 2024 and is subject to approval by Glatfelter shareholders and completion of customary closing conditions.